|
|
Phase III Study of Chemo/Hormonal Therapy vs Androgen Ablation Alone as Initial Therapy in Patients With Unresectable/Metastatic Adenocarcinoma of the Prostate
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
no age specified
|
|
|
|
NCI
|
|
|
|
MDA-DM-95231 NCI-G96-1044, NCT00002855
|
|
|
Objectives - Determine the clinical benefit, as measured by time to progression and overall survival, of chemo/hormonal therapy compared to androgen ablation alone, when given as the initial systemic treatment in patients with acinar adenocarcinoma of the prostate that is not amenable to local therapy.
- Validate the clinical significance of PSA criteria for progression.
Entry Criteria Disease Characteristics:
- Histologically proven acinar adenocarcinoma of the prostate
- Metastatic or locally advanced disease that either is not appropriately treated with surgery or radiation, or has recurred
following previous
"definitive" local therapy
- No CNS metastases
- No histologic subtypes, such as pure ductal or any component of small
cell carcinoma
- Elevated PSA (at least 1.0 ng/mL in patients with prior prostatectomy or 4.0 ng/mL in those with prostate in place)
Prior/Concurrent Therapy:
Biologic therapy: Chemotherapy: - No prior cytotoxic systemic therapy
Endocrine therapy: - Prior androgen deprivation therapy allowed if given for no
more than 6 months to downstage primary
- No androgen deprivation therapy within 1 year prior to
study
Radiotherapy: - No prior cytotoxic systemic therapy (including systemic
strontium-89 irradiation)
- Prior definitive radiotherapy to the prostate and/or one
metastatic site allowed
- At least 8 weeks since radiotherapy to the pelvis
- At least 3 weeks since radiotherapy to a single metastatic
site
Surgery: - Prior prostatectomy allowed
Other: - No concurrent anti-anginal therapy or aggressive
anticoagulants
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - Absolute neutrophil count greater than 1,500/mm3
- Platelet count greater than 100,000/mm3
Hepatic: - Conjugated bilirubin no greater than 0.8 mg/dL or total
bilirubin no greater than 1.5 mg/dL
- Transaminase no greater than 4 times upper limit of
normal
Renal: - Creatinine clearance at least 40 mL/min
Cardiovascular: - No evidence of bifascicular block on EKG
- No evidence of active ischemia on EKG
- No prior history of transient ischemic attack
- No evidence of congestive heart failure
Other: - No active peptic ulcer disease
- No regular use of antacid or H2 blockers
- No known or predicted achlorhydria
- No concurrent use of terfenadine, astemizole, omeprazole, or
cisapride
- No second malignancy unless curatively treated
- No history of deep venous thrombosis
- No history of pulmonary embolism
- No serious co-morbidity
- HIV negative
Expected Enrollment 368A total of 368 patients will be accrued for this study. Outline This is a randomized study. Patients are randomized to 1 of 2 treatment arms.
Trial Contact Information
Trial Lead Organizations M. D. Anderson Cancer Center at University of Texas | | | Randall Millikan, MD, PhD, Protocol chair | | | |
Registry Information | | Official Title | | A PHASE 3 TRIAL OF ANDROGEN ABLATION ALONE VS. CHEMO/HORMONAL THERAPY AS INITIAL TREATMENT OF UNRESECTABLE/METASTATIC ADENOCARCINOMA OF THE PROSTATE | | Trial Start Date | | 1996-08-28 | | Registered in ClinicalTrials.gov | | NCT00002855 | | Date Submitted to PDQ | | 1996-08-28 | | Information Last Verified | | 2004-01-09 | | NCI Grant/Contract Number | | P30-CA16672 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|